Stockreport

Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”

DIMENSION THERAPEUTICS  (DMTX) 
US:NASDAQ Investor Relations: investors.dimensiontx.com
PDF REGENXBIO Waives Matching Rights CAMBRIDGE, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (“Dimension”) (NASDAQ:DMTX) announced today that t [Read more]